Ipsen's Iqirvo® receives U.S. FDA accelerated approval

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Macau , Paris , France General , France , United Kingdom , China , Hong Kong , Washington , Taiwan , American , Ipsen Euronext , Clin Gastroenterol Hepatol , Carol Roberts , Christelle Huguet , Anna Gibbins , Ipsen Iqirvo , Rachel Reiff , Kris Kowdley , Nicolas Bogler , Amy Wolf , Liver Institute , Ipsen Pharmaceuticals Inc , Fibrotic Liver Disease Consortium Investigators , Drug Administration , Newborn Development , Head Of Research , European Medicines Agency , Regulatory Agency , Ipsen Pharmaceuticals , Executive Vice President , New England Journal , Important Safety Information , Liver Institute Northwest , Executive President , United Kingdom Medicines , Induced Liver Injury , Adverse Event , Reproductive Potential , Prescribing Information , Breakthrough Therapy Designation , Rare Disease , Sponsored Leveli American Depositary Receipt , French Autorit , Des March , Universal Registration Document , Primary Biliary , Liver Disease Consortium , Increasing Prevalence , Primary Biliary Cholangitis , Reduced Mortality With , Clin Gastroenterol ,